Evaluation of Injury Risk Factors and Effects of Individualized Exercise Program in Basketball and Volleyball Athletes (IRISPORT)

April 3, 2026 updated by: Ali Ömer Acar, Acibadem University

Evaluation of Injury Risk Factors With Clinical/Functional Tests and Effects of Individualized Exercise Program in University Basketball and Volleyball Athletes: A Non-Randomized Parallel-Group Study

This study aims to identify injury risk factors using a clinical/functional test battery in university basketball and volleyball athletes, to develop individualized exercise prescriptions for athletes scoring below established cut-off values on each test, and to evaluate the effects of an 8-week intervention program on test parameters.

As a secondary aim, all participants will be monitored prospectively over a 6-month season to assess the incidence of injuries and health problems, and to evaluate the contribution of the individualized program to injury-related health outcomes.

The study consists of four phases: (1) baseline cross-sectional assessment (T0), (2) 8-week individualized exercise intervention for athletes below cut-off thresholds, (3) post-intervention reassessment (T1), and (4) 6-month prospective injury surveillance (T2).

Study Overview

Detailed Description

BACKGROUND:

Musculoskeletal injuries in athletes represent a significant sports medicine and public health problem due to restricted training/competition participation, prolonged rehabilitation, and increased re-injury risk. Epidemiological data indicate that basketball and volleyball athletes carry elevated risk for lower extremity sprains/strains, knee ligament injuries, and overhead-related shoulder pathologies. University athletes are particularly vulnerable given the concurrent demands of intense academic schedules and high training loads.

Clinical/functional tests can systematically identify modifiable risk factors including neuromuscular control, balance, flexibility, and functional strength. The Y-Balance Test (YBT-LQ), Hop-for-Distance Test (Limb Symmetry Index), Active Straight Leg Raise (ASLR), Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST), and Glenohumeral Internal Rotation Deficit (GIRD) assessment are employed in this study, each with established reliability and predictive validity.

STUDY DESIGN:

This is a non-randomized, parallel-group interventional study. Athletes scoring below literature-defined cut-off values on any test receive test-specific individualized exercise prescriptions (Intervention Group), while athletes meeting all cut-off thresholds receive no intervention and serve as the observation group. Both groups undergo identical assessment at T0 and T1, and are monitored for injuries through T2.

INTERVENTION:

The 8-week individualized exercise program is prescribed based on each athlete's specific deficits:

  • YBT-LQ below cut-off (composite score less than 94% or asymmetry greater than 4 cm): Dynamic balance and proprioception exercises
  • Hop Test LSI below 90%: Plyometric control and symmetry exercises
  • ASLR below 70 degrees: Hamstring/posterior chain flexibility exercises
  • CKCUEST below cut-off (males less than 21, females less than 23 touches): Scapular stability and upper extremity endurance exercises
  • GIRD above cut-off (internal rotation deficit greater than 20 degrees or total rotation difference greater than 5 degrees): Posterior shoulder capsule and rotator cuff exercises

Frequency: 3 days/week, 20-30 minutes per session. First 2 weeks supervised, subsequent weeks partially independent. Weekly compliance logged.

INJURY SURVEILLANCE (T2):

All participants are monitored for 6 months using IOC 2020 Consensus Statement methodology. Events are classified by type (injury/illness), onset (acute/overuse), anatomical region, severity (time-loss days), and recurrence status. Participant reports are cross-checked with team staff records where available.

STATISTICAL ANALYSIS:

Descriptive statistics (mean +/- SD, median, frequencies). T0-T1 comparisons: paired t-test or Wilcoxon signed-rank test (only athletes below cut-off for each respective test). Between-branch comparisons: independent t-test / Mann-Whitney U, chi-square / Fisher exact test. Effect sizes (Cohen's d). Injury incidence comparison between intervention and observation groups at T2. Significance level: p less than 0.05.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Istanbul, Turkey (Türkiye)
        • Acibadem Mehmet Ali Aydinlar University, Department of Physiotherapy and Rehabilitation
        • Contact:
        • Principal Investigator:
          • Ali Omer Acar

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Active member of Acibadem University basketball or volleyball team
  • Regular training within the past 6 months
  • Age 18 years or older
  • Willing to participate and provide written informed consent
  • Physical and cognitive capacity to complete test protocols

Exclusion Criteria:

  • Surgical intervention within the past 6 months
  • Acute musculoskeletal injury within the past 2 weeks (acute sprain/strain/contusion etc.) that would preclude testing
  • History of vestibular disorder, neurological disease, or systemic condition that may affect balance testing
  • Uncontrolled cardiovascular disease/hypertension or other medical condition contraindicating exercise
  • Pregnancy or within the first 6 months postpartum (female athletes)
  • Refusal to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Individualized Exercise Intervention
Athletes scoring below established literature cut-off values on one or more clinical/functional tests at baseline (T0). Each athlete receives a test-specific individualized exercise prescription targeting their identified deficits. The program is administered 3 days/week for 8 weeks (20-30 min/session), with supervised sessions in weeks 1-2 and partially independent sessions in weeks 3-8.

An 8-week individualized exercise program prescribed based on each athlete's baseline test deficits. Components include:

  1. Dynamic balance/proprioception exercises (for YBT-LQ deficit): single-leg balance progressions, 3-direction reach drills, BOSU balance exercises.
  2. Plyometric control and symmetry exercises (for Hop Test LSI deficit): single-leg hop-and-stick, lateral hops, eccentric step-up/step-down.
  3. Hamstring/posterior chain flexibility exercises (for ASLR deficit): static hamstring stretching with strap, PNF contract-relax, seated hamstring stretch.
  4. Scapular stability and upper extremity endurance exercises (for CKCUEST deficit): plank shoulder taps, bear crawl, side plank progressions.
  5. Posterior shoulder capsule and rotator cuff exercises (for GIRD deficit): cross-body stretch, sleeper stretch, external rotation with resistance band.

Dosage: 3 sessions/week, 20-30 minutes/session. Progressive overload applied. Weekly compliance monitored.

No Intervention: Observation (No Intervention)
Athletes meeting all literature-defined cut-off thresholds on every clinical/functional test at baseline (T0). These athletes continue their routine training without additional exercise intervention. They undergo the same T0 and T1 assessments and 6-month injury surveillance as the intervention group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Y-Balance Test Lower Quarter (YBT-LQ) Composite Score
Time Frame: Baseline (T0) and 8 weeks (T1)
Composite score calculated as [(Anterior + Posteromedial + Posterolateral) / (3 x Leg Length)] x 100. Assessed bilaterally. Cut-off: composite score less than 94% or right-left asymmetry greater than 4 cm.
Baseline (T0) and 8 weeks (T1)
Change in Hop-for-Distance Test Limb Symmetry Index (LSI)
Time Frame: Baseline (T0) and 8 weeks (T1)
LSI calculated as (Weaker Side / Stronger Side) x 100. Three trials per limb, best distance recorded. Cut-off: LSI less than 90%.
Baseline (T0) and 8 weeks (T1)
Change in Active Straight Leg Raise (ASLR) Hip Flexion Angle
Time Frame: Baseline (T0) and 8 weeks (T1)
Hip flexion range of motion measured by goniometry in supine position with knee extended. Two measurements per limb, average recorded. Cut-off: hip flexion less than 70 degrees.
Baseline (T0) and 8 weeks (T1)
Change in Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST) Score
Time Frame: Baseline (T0) and 8 weeks (T1)
Number of hand touches in 15 seconds from push-up position with hands 91 cm apart. Three trials, best score recorded. Cut-off: males less than 21 touches, females less than 23 touches.
Baseline (T0) and 8 weeks (T1)
Change in Glenohumeral Internal Rotation Deficit (GIRD)
Time Frame: Baseline (T0) and 8 weeks (T1)
Internal and external rotation measured by goniometry in supine (shoulder 90 degrees abduction, elbow 90 degrees flexion), scapula stabilized. GIRD = non-dominant IR minus dominant IR. Cut-off: IR deficit greater than 20 degrees or total rotation difference greater than 5 degrees.
Baseline (T0) and 8 weeks (T1)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Musculoskeletal Injuries and Health Problems
Time Frame: 6 months (T0 through T2)
Prospective injury surveillance using IOC 2020 Consensus Statement methodology. Events classified by type (injury/illness), onset (acute/overuse), anatomical region, severity (time-loss: 0, 1-3, 4-7, 8-28, greater than 28 days), and recurrence. Comparison between intervention and observation groups.
6 months (T0 through T2)
Pittsburgh Sleep Quality Index (PSQI) Global Score
Time Frame: Baseline (T0)
Self-report measure of sleep quality over the past month. 19 items, 7 components, global score 0-21. Higher scores indicate poorer sleep quality. Global PSQI greater than 5 indicates clinically significant poor sleep quality.
Baseline (T0)
Borg Rating of Perceived Exertion (RPE)
Time Frame: Baseline (T0)
Perceived exertion level assessed using the Borg RPE Scale (6-20).
Baseline (T0)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ali Omer Acar, Acibadem Mehmet Ali Aydinlar University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

April 3, 2026

First Submitted That Met QC Criteria

April 3, 2026

First Posted (Actual)

April 9, 2026

Study Record Updates

Last Update Posted (Actual)

April 9, 2026

Last Update Submitted That Met QC Criteria

April 3, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ACU-FTR-AOA4
  • 2026-04/168 (Other Identifier: ATADEK Ethics Committee Approval Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe